A pre-clinical study of selinexor for primary central nervous system lymphoma


  • Selinexor blocks tumor growth, promotes an anti-tumor immune response, and increases survival in a mouse model of primary central nervous system lymphoma (PCNSL).

Why this matters

  • PCNSL is a rare and aggressive form of non-Hodgkin lymphoma, with limited treatment options and a 5-year survival rate of 30%.

  • Selinexor is a selective inhibitor of nuclear export which binds to cargo pocket of exportin XPO1 causing nuclear accumulation of tumor suppressor proteins and cell cycle regulators.

  • Selinexor may be a good candidate for the treatment of PCNSL; however, extensive pre-clinical and clinical trials would be needed to prove this.

¿Quiere leer más?

Inicie sesión o regístrese para acceder a todo el contenido de Neurodiem.

¿Ya tiene una cuenta? Inicie sesión

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.